Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
418.00
+8.00 (1.95%)
Apr 28, 2026, 2:00 PM CST
248.33%
Market Cap 33.92B
Revenue (ttm) n/a
Net Income (ttm) -1.02B
Shares Out 82.73M
EPS (ttm) -12.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232,611
Average Volume 909,686
Open 410.00
Previous Close 410.00
Day's Range 404.00 - 421.50
52-Week Range 111.00 - 510.00
Beta 0.20
RSI 52.39
Earnings Date Apr 24, 2026

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.